Expression of thimet oligopeptidase (THOP) modulated by oxidative stress in human multidrug resistant (MDR) leukemia cells. 2023

Raquel Leão Neves, and Alyne Marem, and Bruno Carmona, and Júlia Galanakis Arata, and Marcos Paulo Cyrillo Ramos, and Giselle Zenker Justo, and Fabiana Henriques Machado de Melo, and Vitor Oliveira, and Marcelo Yudi Icimoto
Departamento de Biofísica, Universidade Federal de São Paulo, São Paulo, São Paulo, Brazil.

Thimet oligopeptidase (THOP) is a cytosolic metallopeptidase known to regulate the fate of post-proteasomal peptides, protein turnover and peptide selection in the antigen presentation machinery (APM) system. Oxidative stress influences THOP expression and regulates its proteolytic activity, generating variable cytosolic peptide levels, possibly affecting the immune evasion of tumor cells. In the present work, we examined the association between THOP expression/activity and stress oxidative resistance in human leukemia cells using the K562 cell line, a chronic myeloid leukemia (CML), and the multidrug-resistant (MDR) Lucena 1 (K562-derived MDR cell line) as model. The Lucena 1 phenotype was validated under vincristine treatment and the relative THOP1 mRNA levels and protein expression compared to K562 cell line. Our data demonstrated increased THOP1 gene and protein levels in K562 cells in contrast to the oxidative-resistant Lucena 1, even after H2O2 treatment, suggesting an oxidative stress dependence in THOP regulation. Further, it was observed higher basal levels of reactive oxygen species (ROS) in K562 compared to Lucena 1 cell line using DHE fluorescent probe. Since THOP activity is dependent on its oligomeric state, we also compared its proteolytic activity under reducing agent treatment, which demonstrated that its function modulation with respect to changes in redox state. Finally, the mRNA expression and FACS analyses demonstrated a reduced expression of MHC I only in K562 cell line. In conclusion, our results highlight THOP redox modulation, which could influence antigen presentation in multidrug resistant leukemia cells.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006861 Hydrogen Peroxide A strong oxidizing agent used in aqueous solution as a ripening agent, bleach, and topical anti-infective. It is relatively unstable and solutions deteriorate over time unless stabilized by the addition of acetanilide or similar organic materials. Hydrogen Peroxide (H2O2),Hydroperoxide,Oxydol,Perhydrol,Superoxol,Peroxide, Hydrogen
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D018384 Oxidative Stress A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products (Sies, Oxidative Stress, 1991, pxv-xvi). Anti-oxidative Stress,Antioxidative Stress,DNA Oxidative Damage,Nitro-Oxidative Stress,Oxidative Cleavage,Oxidative DNA Damage,Oxidative Damage,Oxidative Injury,Oxidative Nitrative Stress,Oxidative Stress Injury,Oxidative and Nitrosative Stress,Stress, Oxidative,Anti oxidative Stress,Anti-oxidative Stresses,Antioxidative Stresses,Cleavage, Oxidative,DNA Damage, Oxidative,DNA Oxidative Damages,Damage, DNA Oxidative,Damage, Oxidative,Damage, Oxidative DNA,Injury, Oxidative,Injury, Oxidative Stress,Nitrative Stress, Oxidative,Nitro Oxidative Stress,Nitro-Oxidative Stresses,Oxidative Cleavages,Oxidative DNA Damages,Oxidative Damage, DNA,Oxidative Damages,Oxidative Injuries,Oxidative Nitrative Stresses,Oxidative Stress Injuries,Oxidative Stresses,Stress Injury, Oxidative,Stress, Anti-oxidative,Stress, Antioxidative,Stress, Nitro-Oxidative,Stress, Oxidative Nitrative,Stresses, Nitro-Oxidative
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug
D020014 K562 Cells An ERYTHROLEUKEMIA cell line derived from a CHRONIC MYELOID LEUKEMIA patient in BLAST CRISIS. Cells, K562

Related Publications

Raquel Leão Neves, and Alyne Marem, and Bruno Carmona, and Júlia Galanakis Arata, and Marcos Paulo Cyrillo Ramos, and Giselle Zenker Justo, and Fabiana Henriques Machado de Melo, and Vitor Oliveira, and Marcelo Yudi Icimoto
November 2023, Journal of chemical neuroanatomy,
Raquel Leão Neves, and Alyne Marem, and Bruno Carmona, and Júlia Galanakis Arata, and Marcos Paulo Cyrillo Ramos, and Giselle Zenker Justo, and Fabiana Henriques Machado de Melo, and Vitor Oliveira, and Marcelo Yudi Icimoto
January 2021, Anti-cancer agents in medicinal chemistry,
Raquel Leão Neves, and Alyne Marem, and Bruno Carmona, and Júlia Galanakis Arata, and Marcos Paulo Cyrillo Ramos, and Giselle Zenker Justo, and Fabiana Henriques Machado de Melo, and Vitor Oliveira, and Marcelo Yudi Icimoto
November 1988, Cancer research,
Raquel Leão Neves, and Alyne Marem, and Bruno Carmona, and Júlia Galanakis Arata, and Marcos Paulo Cyrillo Ramos, and Giselle Zenker Justo, and Fabiana Henriques Machado de Melo, and Vitor Oliveira, and Marcelo Yudi Icimoto
August 1995, The Journal of clinical investigation,
Raquel Leão Neves, and Alyne Marem, and Bruno Carmona, and Júlia Galanakis Arata, and Marcos Paulo Cyrillo Ramos, and Giselle Zenker Justo, and Fabiana Henriques Machado de Melo, and Vitor Oliveira, and Marcelo Yudi Icimoto
July 2013, Oncogene,
Raquel Leão Neves, and Alyne Marem, and Bruno Carmona, and Júlia Galanakis Arata, and Marcos Paulo Cyrillo Ramos, and Giselle Zenker Justo, and Fabiana Henriques Machado de Melo, and Vitor Oliveira, and Marcelo Yudi Icimoto
July 2017, FEBS open bio,
Raquel Leão Neves, and Alyne Marem, and Bruno Carmona, and Júlia Galanakis Arata, and Marcos Paulo Cyrillo Ramos, and Giselle Zenker Justo, and Fabiana Henriques Machado de Melo, and Vitor Oliveira, and Marcelo Yudi Icimoto
October 1999, Journal of cell science,
Raquel Leão Neves, and Alyne Marem, and Bruno Carmona, and Júlia Galanakis Arata, and Marcos Paulo Cyrillo Ramos, and Giselle Zenker Justo, and Fabiana Henriques Machado de Melo, and Vitor Oliveira, and Marcelo Yudi Icimoto
June 1986, Proceedings of the National Academy of Sciences of the United States of America,
Raquel Leão Neves, and Alyne Marem, and Bruno Carmona, and Júlia Galanakis Arata, and Marcos Paulo Cyrillo Ramos, and Giselle Zenker Justo, and Fabiana Henriques Machado de Melo, and Vitor Oliveira, and Marcelo Yudi Icimoto
May 2009, The Journal of biological chemistry,
Raquel Leão Neves, and Alyne Marem, and Bruno Carmona, and Júlia Galanakis Arata, and Marcos Paulo Cyrillo Ramos, and Giselle Zenker Justo, and Fabiana Henriques Machado de Melo, and Vitor Oliveira, and Marcelo Yudi Icimoto
January 1999, Experimental hematology,
Copied contents to your clipboard!